Hedge Funds Are Dumping Voyager Therapeutics Inc (VYGR)

Page 1 of 2

The worries about the election and the ongoing uncertainty about the path of interest-rate increases have been keeping investors on the sidelines. Of course, most hedge funds and other asset managers have been underperforming main stock market indices since the middle of 2015. Interestingly though, smaller-cap stocks registered their best performance relative to the large-capitalization stocks since the end of the June quarter, suggesting that this may be the best time to take a cue from their stock picks. In fact, the Russell 2000 Index gained more than 15% since the beginning of the third quarter, while the Standard and Poor’s 500 benchmark returned less than 6%. This article will lay out and discuss the hedge fund and institutional investor sentiment towards Voyager Therapeutics Inc (NASDAQ:VYGR).

Voyager Therapeutics Inc (NASDAQ:VYGR) investors should be aware of a decrease in support from the world’s most successful money managers lately. VYGR was in 6 hedge funds’ portfolios at the end of September. There were 7 hedge funds in our database with VYGR positions at the end of the previous quarter. At the end of this article we will also compare VYGR to other stocks including BioSpecifics Technologies Corp. (NASDAQ:BSTC), Compugen Ltd. (USA) (NASDAQ:CGEN), and American Public Education, Inc. (NASDAQ:APEI) to get a better sense of its popularity.

Follow Voyager Therapeutics Inc. (NASDAQ:VYGR)

We care about hedge fund sentiment because historically hedge funds’ stock picks delivered strong risk adjusted returns. There are certain segments of the market where hedge funds’ stock picks performed much better than its benchmarks. For instance, the 30 most popular mid-cap stocks among the best performing hedge funds returned 18% over the last 12 months outpacing S&P 500 Index by more than 10 percentage points. We developed this strategy 2.5 years ago and started sharing its picks in our quarterly newsletter. It bested the S&P 500 Index ETFs by delivering a solid 39% vs. 22% gain for its benchmarks.

testing, gene, disrder, double, breakthrough, engineering, disease, technology, medicine, therapy, biology, clinical, strand, chromosomes, health, conceptual, genetics,


Now, let’s take a glance at the new action regarding Voyager Therapeutics Inc (NASDAQ:VYGR).

What have hedge funds been doing with Voyager Therapeutics Inc (NASDAQ:VYGR)?

At the end of the third quarter, a total of 6 of the hedge funds tracked by Insider Monkey held long positions in this stock, a change of -14% from the second quarter of 2016. Below, you can check out the change in hedge fund sentiment towards VYGR over the last 5 quarters. So, let’s review which hedge funds were among the top holders of the stock and which hedge funds were making big moves.


According to publicly available hedge fund and institutional investor holdings data compiled by Insider Monkey, Brookside Capital, led by Bain Capital, holds the largest position in Voyager Therapeutics Inc (NASDAQ:VYGR). Brookside Capital has a $18.2 million position in the stock, comprising 1.2% of its 13F portfolio. The second most bullish fund manager is Partner Fund Management, led by Christopher James, holding a $16.3 million position; the fund has 0.5% of its 13F portfolio invested in the stock. Some other peers with similar optimism consist of Eli Casdin’s Casdin Capital, James E. Flynn’s Deerfield Management and Phill Gross and Robert Atchinson’s Adage Capital Management. We should note that none of these hedge funds are among our list of the 100 best performing hedge funds which is based on the performance of their 13F long positions in non-microcap stocks.

Page 1 of 2